Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Yip

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
BJU International|May 24, 2021
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.
BMJ Open|January 26, 2022
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trialPeey Sei Kok, Patrick M Forde, Brett Hughes, et al.
Future Oncology (London, England)|September 28, 2023
ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissueAntony J Mersiades, Benjamin J Solomon, David M Thomas, et al.
Neuro-Oncology|May 13, 2021
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU studyHao-Wen Sim, Kerrie L McDonald, Zarnie Lwin, et al.
Journal for Immunotherapy of Cancer|June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trialYoland Antill, Peey-Sei Kok, Kristy Robledo, et al.
BMJ Open|February 10, 2025
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 gliomaKristen McParland, Eng-Siew Koh, Benjamin Kong, et al.
Cancers|January 8, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)Deborah Smith, Kristy P Robledo, Sonia Yip, et al.
BMJ Open|September 14, 2022
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastomaBenjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET TrialSebastian Medina, Naoto Tokuyama, Vaishnavi Putcha, et al.
Nature Communications|February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATELavinia Tan, Chris Brown, Antony Mersiades, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
BJU International|May 24, 2021
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.
BMJ Open|January 26, 2022
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trialPeey Sei Kok, Patrick M Forde, Brett Hughes, et al.
Future Oncology (London, England)|September 28, 2023
ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissueAntony J Mersiades, Benjamin J Solomon, David M Thomas, et al.
Neuro-Oncology|May 13, 2021
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU studyHao-Wen Sim, Kerrie L McDonald, Zarnie Lwin, et al.
Journal for Immunotherapy of Cancer|June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trialYoland Antill, Peey-Sei Kok, Kristy Robledo, et al.
BMJ Open|February 10, 2025
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 gliomaKristen McParland, Eng-Siew Koh, Benjamin Kong, et al.
Cancers|January 8, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)Deborah Smith, Kristy P Robledo, Sonia Yip, et al.
BMJ Open|September 14, 2022
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastomaBenjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET TrialSebastian Medina, Naoto Tokuyama, Vaishnavi Putcha, et al.
Nature Communications|February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATELavinia Tan, Chris Brown, Antony Mersiades, et al.
Pageof 4